Medical Xpress

APRIL 22, 2023

Repairing or replacing injured tendons or similar load-bearing tissues represents one of the major challenges in clinical medicine. Natural tendons are water-rich tissues exhibiting outstanding mechanical strength and durability. Their mechanical properties originate from sophisticated microscale structures involving stiff collagen fibrils aligned in parallel and interlaced with soft water-retaining biopolymers.

Engineer 111

Engineer Development Medicine 111

ECRG Media's Clinical Research Podcast

APRIL 22, 2023

Don't forget to Subscribe for new content! Merch: [link] Subscribe: / eliteclinicalrese. Email: eliteclinicalgroup@gmail.com Podcast: [link] Steemit: [link] Advertise: eliteclinicalgroup@gmail.com Watch: » Industry News: [link] » All Videos: [link] » Interview Recaps: [link] » Glassdoor Reviews: [link] We do: » Insider Interviews » Resume Reviews » Question and Answer » Discuss all things Clinical Research » News and Product Reviews » Education Elite Clinical Research Group or ECRG for

Clinical Research 52

Clinical Research Research Production 52

The Pharma Data

APRIL 22, 2023

WHO/UNICEF have started the Immunization Annual Data Collection Process We are pleased to announce that the World Health Organization (WHO) / United Nations Children’s Fund (UNICEF) electronic Joint Reporting Form on Immunization (eJRF), is open for completion since March 1st and it covers reporting data for 2022. The eJRF is an online data collection portal, open to all Member States, Reporting Entities, and Associate Members for the collection of immunization performance data.

Vaccination 40

Vaccination Vaccine 40

Drug Patent Watch

APRIL 22, 2023

This chart shows the pharmaceutical companies with the most syrup dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most syrup dosed drugs… The post Which pharmaceutical companies have the most syrup dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 96

Drugs 96

Advertisement

Clinical Supply

The Pharma Data

APRIL 22, 2023

Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma. The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies and harsh chemotherapy drugs. For the first time, Northwestern University scientists have discovered it is possible to isolate a tumor’s attack cells non-invasively from blood, rather than from tumors.

Engineer 40

Engineer Scientist Clinical Trials Clinical Trials 40

The Pharma Data

APRIL 22, 2023

WHO releases first-ever Standard on universal access to rapid TB diagnostics The World Health Organization (WHO) has just released for the first-time – the WHO standard: Universal access to rapid tuberculosis diagnostics , setting benchmarks to: achieve universal access to WHO-recommended rapid diagnostics (WRDs); increase bacteriologically-confirmed TB and detection of drug resistance; and reduce the time to diagnosis.

Drugs 40

Drugs 40

The Pharma Data

APRIL 22, 2023

The current COVID-19 vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. Focusing on the T-cell instead, Penn State researchers partnered with Evaxion Biotech on a study that was the first to demonstrate the effectiveness of an artificial intelligence-generated vaccine in a live viral challenge model.

Vaccination 40

Vaccination Vaccine Protein Antibody 40

The Pharma Data

APRIL 22, 2023

New research shows that several anti-obesity medications could be manufactured and profitability sold worldwide at far lower estimated lower prices compared to their high costs, according to a new study in Obesity, The Obesity Society’s (TOS) flagship journal. “Access to medicine is a fundamental element of the human right to health. While the obesity pandemic grows, especially amongst low-income communities, effective medical treatments remain inaccessible for millions in need.

Licensing 40

Licensing Licensing Medicine Research 40

The Pharma Data

APRIL 22, 2023

Multiple sclerosis (MS) is a devastating autoimmune disease that destroys the protective myelin covering around nerves, disrupting communication between the brain and body, and causing patients’ ability to move and function to progressively decline. The Atlas of MS reported in 2020 that someone is diagnosed with MS every five minutes around the world, adding to about 2.8 million individuals that currently have to live with the disease.

Immune Response 40

Immune Response Engineer In-Vivo Containment 40

The Pharma Data

APRIL 22, 2023

Novo Nordisk raises sales and operating profit outlook for 2023 Novo Nordisk today announced the sales and operating profit growth at constant exchange rates (CER) for the first three months of 2023 and that the full-year sales and operating profit outlook at CER has been raised. In the first three months of 2023, Novo Nordisk’s sales increased by 25% and operating profit increased by 28%, both at CER.

Sales 40

Sales Contract Manufacturing Manufacturing Medicine 40

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

The Pharma Data

APRIL 22, 2023

Bristol Myers Squibb Submits Application for Abecma®, a CAR T Cell Therapy, for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least Two Prior Therapies Bristol-Myers Squibb K.K. announced today that the company has submitted the supplemental New Drug Application for the manufacturing and marketing approval of an additional indication for Abecma® (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy,

Antibody 40

Antibody Protein Bacteria Drugs 40

The Pharma Data

APRIL 22, 2023

Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from several COVID-19 clinical and real-world evidence studies being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). A Phase 3 clinical study demonstrated that Veklury ® (remdesivir) was generally well tolerated in people with moderate to severe renal impairment.

HR 40

HR RNA Development Trials 40

The Pharma Data

APRIL 22, 2023

Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc. Sanofi announced today that it has withdrawn and refiled its Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Sanofi’s pending acquisition of Provention Bio, Inc.

Regulation 40

Regulation Vaccination Vaccine Medicine 40

The Pharma Data

APRIL 22, 2023

A research team led by the National Cancer Centre Singapore (NCCS) with members from Duke-NUS Medical School, KK Women and Children’s Hospital, A*STAR’s Singapore Immunology Network (SIgN), the University of Southampton and the Alan Turing Institute, has discovered how cancer evades the immune system and metastasises in the body, and explores how to shut down this dangerous feature.

RNA 40

RNA Research Development 40

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

The Pharma Data

APRIL 22, 2023

Cocktail of modified antibodies provides strong effect against SARS-CoV-2 Is it possible to improve the antibodies that the body produces to fight SARS-CoV2? In a study led by researchers from Lund University in Sweden, this was investigated by redesigning antibodies and combining them against the virus. The modified antibodies have been tested in human cells and with mice.

Antibody 40

Antibody Immune Response Protein Research 40

The Pharma Data

APRIL 22, 2023

Sanofi, AstraZeneca and Sobi simplify contractual agreements Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus (nirsevimab) in the United States (U.S.). Under the new and updated arrangements, Sobi will terminate its participation agreement with AstraZeneca, and Sanofi and AstraZeneca will update the Collaboration Agreement so that Sanofi has full commercial control of nirsevimab in the U.S.

Antibody 40

Antibody Sales Development Marketing 40

The Pharma Data

APRIL 22, 2023

Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma U.S. FDA accepted Bristol Myers Squibb and 2seventy bio’s supplemental Biologics License Application and has assigned a target action date of December 16, 2023 European Medicines Agency has validated Bristol Myers Squibb’s Type II variation application for Abecma Bristol Myers Squibb’s supplemental New Drug Application for Abecm

Licensing 40

Licensing Licensing Medicine Drugs 40

The Pharma Data

APRIL 22, 2023

UC Davis Health researchers have dosed the second participant in their clinical trial looking to identify a potential cure for HIV utilizing CAR T-cell therapy. The novel study uses immunotherapy. It involves taking a patient’s own white blood cells, called T-cells, and modifying them so they can identify and target HIV cells to control the virus without medication.

Clinical Trials 40

Clinical Trials Clinical Trials Trials In-Vitro 40

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials